Developer/Manufacturer Approach Doses Capacity to end 2021
ModernamRNA2950m
BioNTech/PfizermRNA21,300m
CanSino BiologicsAdenovirus vector1N/A
Johnson & Johnson (Janssen)Adenovirus vector11,100m
Oxford/AstraZenecaAdenovirus vector12,940m
NovavaxProtein subunit nanoparticle21,350m
Sinopharm/WuhanInactivated virus2N/A
Sinopharm/BeijingInactivated virus2N/A
SinovacInactivated virus2350m
GamaleyaAdenovirus vector2100m
Bharat BiotechInactivated virus2N/A